Parijat Saurav Joy1, Achuta Kumar Guddati2, Iuliana Shapira3. 1. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA. 2. Division of Hematology/Oncology, Tulane University, Tulane Avenue, New Orleans, LA, 70125, USA. drgakumar@yahoo.com. 3. Division of Hematology/Oncology, SUNY Downstate Medical Center, Brooklyn, NY, 11203, USA.
Abstract
BACKGROUND: Chemotherapy-induced cardiomyopathy is a critical complication of treatment for cancer. The emotional stress of a cancer diagnosis, ongoing chemotherapy, abnormal cancer-related wasting syndrome may contribute to cardiac morbidity in these patients. The burden of Takotsubo Cardiomyopathy (TCM) in cancer patients is unknown. The incidence of TCM and related outcomes in cancer patients was investigated in this study. METHODS: The 2007-2013 National Inpatient Sample (NIS) was analyzed for patients with a prior and new diagnosis of TCM with and without malignancy. Risk factors for mortality were adjusted for associated conditions by multivariable logistic regression analysis. RESULTS: From 2007 to 2013, an estimated 122,855 adults were admitted with a diagnosis of TCM. In 2013, the incidence of admissions in US of patients with coexisting TCM and malignancy was 1.13%. Patients admitted for TCM with coexisting malignancy had a significantly higher mortality (13.8 vs. 2.9%, p < 0.0001), length of stay (7 vs. 4 days, p < 0.0001) and total charges ($29,291 vs. $36,231, p < 0.0001), compared to those with no malignancy. In patients with a primary diagnosis of TCM and without any underlying malignancy, males had a higher mortality (4.02 vs. 1.03%, p < 0.0001), whereas there was no gender difference in mortality in those with coexisting malignancy (6.25 vs. 6.45%, p = 0.965). On multivariable logistic regression analysis, risk factors associated with mortality were solid cancer (OR 3.43, p = 0.008), stroke (OR 18.33, p < 0.0001) and heart failure (OR 1.918, p = 0.004). CONCLUSIONS: Outcomes are significantly worse in patients with TCM and malignancy. Hence, this patient population must be regarded as high-risk and early diagnostic consideration for TCM is warranted. Early intervention may help lower mortality, decrease resource utilization and reduce the health care costs in these patients.
BACKGROUND: Chemotherapy-induced cardiomyopathy is a critical complication of treatment for cancer. The emotional stress of a cancer diagnosis, ongoing chemotherapy, abnormal cancer-related wasting syndrome may contribute to cardiac morbidity in these patients. The burden of Takotsubo Cardiomyopathy (TCM) in cancerpatients is unknown. The incidence of TCM and related outcomes in cancerpatients was investigated in this study. METHODS: The 2007-2013 National Inpatient Sample (NIS) was analyzed for patients with a prior and new diagnosis of TCM with and without malignancy. Risk factors for mortality were adjusted for associated conditions by multivariable logistic regression analysis. RESULTS: From 2007 to 2013, an estimated 122,855 adults were admitted with a diagnosis of TCM. In 2013, the incidence of admissions in US of patients with coexisting TCM and malignancy was 1.13%. Patients admitted for TCM with coexisting malignancy had a significantly higher mortality (13.8 vs. 2.9%, p < 0.0001), length of stay (7 vs. 4 days, p < 0.0001) and total charges ($29,291 vs. $36,231, p < 0.0001), compared to those with no malignancy. In patients with a primary diagnosis of TCM and without any underlying malignancy, males had a higher mortality (4.02 vs. 1.03%, p < 0.0001), whereas there was no gender difference in mortality in those with coexisting malignancy (6.25 vs. 6.45%, p = 0.965). On multivariable logistic regression analysis, risk factors associated with mortality were solid cancer (OR 3.43, p = 0.008), stroke (OR 18.33, p < 0.0001) and heart failure (OR 1.918, p = 0.004). CONCLUSIONS: Outcomes are significantly worse in patients with TCM and malignancy. Hence, this patient population must be regarded as high-risk and early diagnostic consideration for TCM is warranted. Early intervention may help lower mortality, decrease resource utilization and reduce the health care costs in these patients.
Authors: Christof Burgdorf; Holger M Nef; Dariusch Haghi; Volkhard Kurowski; Peter W Radke Journal: Ann Intern Med Date: 2010-06-15 Impact factor: 25.391
Authors: K Sattler; I El-Battrawy; S Lang; X Zhou; K Schramm; E Tülümen; F Kronbach; S Röger; M Behnes; J Kuschyk; M Borggrefe; I Akin Journal: Int J Cardiol Date: 2017-02-22 Impact factor: 4.164
Authors: Mohammad Abumayyaleh; Ibrahim El-Battrawy; Marvin Kummer; Thorsten Gietzen; Michael Behnes; Xiao-Bo Zhou; Siegfried Lang; Martin Borggrefe; Ibrahim Akin Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Bala Pushparaji; Teodora Donisan; Dinu V Balanescu; Nicolas Palaskas; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Saamir A Hassan; Konstantinos Dean Boudoulas; Konstantinos Marmagkiolis; Ludhmila Abrahao Hajjar; Cezar A Iliescu Journal: Curr Oncol Rep Date: 2021-09-27 Impact factor: 5.075
Authors: Awad I Javaid; Dominique J Monlezun; Gloria Iliescu; Phi Tran; Alexandru Filipescu; Nicolas Palaskas; Juan Lopez-Mattei; Saamir Hassan; Peter Kim; Mohammad Madjid; Mehmet Cilingiroglu; Konstantinos Charitakis; Konstantinos Marmagkiolis; Cezar Iliescu; Efstratios Koutroumpakis Journal: ESC Heart Fail Date: 2021-10-05